Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 14, 2017

View Archived Issues

Alyeyuba shows good preclinical results for the treatment of cutaneous leishmaniasis

Zafgen begins phase II study of ZGN-1061 in type 2 diabetes

Novel approach to develop tools for detection and monitoring of multiple neurodegenerative diseases

VAXIMM's oral T-cell immunotherapy granted orphan drug status in E.U.

Umecrine Cognition reports favorable results from phase Ib trial of GR-3027

Lef1 regulates hypothalamic neurogenesis and mediates anxiety in a wide variety of animal species

NIAID agrees to support phase I study of Geom Therapeutics' GT-1

Merger between Inspyr Therapeutics and Lewis and Clark Pharmaceuticals completed

First patient with DMD completes 15 months of treatment in Carmeseal-MD expanded access program

Preliminary phase I study of the third-generation EGFR inhibitor TAS-121 in NSCLC patients

First patient dosed in phase Ia study of OncoMed Pharmaceuticals' GITRL-Fc

Otonomy announces financial and business update

ND-L02-s0201 demonstrates efficacy in preclinical lung fibrosis models

FDA accepts for review the NDAs for binimetinib and encorafenib combination

Phase III ESSENCE study of SD-101 in epidermolysis bullosa does not meet primary endpoint

FDA grants orphan drug designation to Reata's omaveloxolone for malignant melanoma

Novel small conductance channel blockers presented by Acesion Pharma

FDA advisory committee recommends approval of Shingrix

AgeneBio wins grant to support GABA-A program for MCI due to Alzheimer's

Vanda reports phase II data on tradipitant in atopic dermatitis

Phase I results presented for resminostat/S-1 combination in pancreatic and biliary tract cancer

Alligator Bioscience enters 4-1BB research agreement with University of Navarra

FDA accepts for review sNDA for mirabegron in combination with solifenacin for overactive bladder

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 22, 2026.
Biohaven reports details on discovery of BHV-2100
BioWorld Science
Transient receptor potential melastatin 3 (TRPM3) is a calcium-permeable TRP channel that is highly expressed in somatosensory neurons, including nociceptors of...
Meta-analysis: Anti-amyloid Alzheimer’s drugs not ‘clinically meaningful’
BioWorld
The ongoing controversy over the effectiveness of anti-amyloid drugs is about to get more heated, after a review of clinical trials showed statistically...
New GABA(B) receptor PAMs revealed in Addex Pharma patents
BioWorld Science
Addex Pharma SA has disclosed new GABA(B) receptor positive allosteric modulators (PAMs) potentially useful for the treatment of chronic cough, urinary...
MMP inhibitors divulged in Accure Therapeutics patent
BioWorld Science
Accure Therapeutics has reported new oligopeptide derivatives acting as matrix metalloproteinase-2 (MMP-2) and MMP-9 inhibitors. As such, they are described as...